Health Canada approves Lumakras (sotorasib), the first and only targeted treatment for patients with KRAS G12C mutated locally advanced or metastatic non--small cell lung cancer


14 September 2021 - Once daily dosing option now available to address KRAS G12C, a driver of tumour growth found in an estimated 10% - 15% of patients with non-small cell lung cancer.

Amgen today announced that Health Canada has approved Lumakras (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small-cell lung cancer who have received at least one prior systemic therapy. 

Lumakras was granted a Notice of Compliance with Conditions based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Read Amgen press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada